A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

March 1, 2020

Study Completion Date

March 1, 2020

Conditions

Non-alcoholic Steatohepatitis (NASH)

Interventions

DRUG

CF102

orally q12h

DRUG

Placebo

orally q12h

Trial Locations (3)

Can-Fite Investigational Site #318, Jerusalem

Can-Fite Investigational Site #319, Nazareth

Can-Fite Investigational Site #311, Petah Tikva